Evidence map›Paper›PMID 22521499›Full record

ArticleNeuropharmacology2013

Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1.

Takaki Kiritoshi, Hao Sun, Wenjie Ren, Shaun R Stauffer, Craig W Lindsley, P Jeffrey Conn, Volker Neugebauer

Abstract read
In one paragraph

Article in Neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 49 citations in OpenAlex.

  1. mGluR5 in ECAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Prenatal exposure to morphine enhances excitability in locus coeruleus neurons.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Nightmares and the Cannabinoids.Current neuropharmacology · 2020
    Review
  16. Article
  17. Review
  18. Prefrontal endocannabinoids, stress controllability and resilience: A hypothesis.Progress in neuro-psychopharmacology & biological psychiatry · 2018
    Review
  19. Article
  20. The cannabinoid system and pain.Neuropharmacology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Takaki KiritoshiDepartment of Neuroscience and Cell Biology, The University of Texas Medical Branch, 301 University Blvd. Galveston, TX 77555-1069, USA. kitakaki@utmb.edu
Hao Sun
Wenjie Ren
Shaun R Stauffer
Craig W Lindsley
P Jeffrey Conn
Volker Neugebauer
The University of Texas Medical Branch at Galveston · USVanderbilt University Medical Center · US

Funding

VISCERAL PAINP01NS011255 · NINDS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI HULSEBOSCH, CLAIRE E · 1985 to 2012
$13.6M
REGULATION OF SIGNALING BY MGLUR5R01MH062646 · NIMH · VANDERBILT UNIVERSITY · PI P Jeffrey Conn, COLLEEN M NISWENDER · 2001 to 2026
$10.9M
PAIN, NOCICEPTION, AND THE AMYGDALAR01NS038261 · NINDS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Volker Neugebauer, Igor Ponomarev · 1999 to 2026
$8.7M
FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPESR01NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 1993 to 2025
$6.2M
Amygdala Serotonin Neurotransmission and Neuropathic PainR01NS081121 · NINDS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GREEN, THOMAS ARTHUR, NEUGEBAUER, VOLKER · 2013 to 2017
$2.3M
NIMH NIH HHS R01 MH062646NINDS NIH HHS NS11255NINDS NIH HHS NS38261NINDS NIH HHS P01 NS011255NINDS NIH HHS R01 NS031373NINDS NIH HHS R01 NS038261NINDS NIH HHS R01 NS081121
6 · The paper itself

Abstract

The medial prefrontal cortex (mPFC) serves executive cognitive functions such as decision-making that are impaired in neuropsychiatric disorders and pain. We showed previously that amygdala-driven abnormal inhibition and decreased output of mPFC pyramidal cells contribute to pain-related impaired decision-making (Ji et al., 2010). Therefore, modulating pyramidal output is desirable therapeutic goal. Targeting metabotropic glutamate receptor subtype mGluR5 has emerged as a cognitive-enhancing strategy in neuropsychiatric disorders, but synaptic and cellular actions of mGluR5 in the mPFC remain to be determined. The present study determined synaptic and cellular actions of mGluR5 to test the hypothesis that increasing mGluR5 function can enhance pyramidal cell output. Whole-cell voltage- and current-clamp recordings were made from visually identified pyramidal neurons in layer V of the mPFC in rat brain slices. Both the prototypical mGluR5 agonist CHPG and a positive allosteric modulator (PAM) for mGluR5 (VU0360172) increased synaptically evoked spiking (E-S coupling) in mPFC pyramidal cells. The facilitatory effects of CHPG and VU0360172 were inhibited by an mGluR5 antagonist (MTEP). CHPG, but not VU0360172, increased neuronal excitability (frequency-current [F-I] function). VU0360172, but not CHPG, increased evoked excitatory synaptic currents (EPSCs) and amplitude, but not frequency, of miniature EPSCs, indicating a postsynaptic action. VU0360172, but not CHPG, decreased evoked inhibitory synaptic currents (IPSCs) through an action that involved cannabinoid receptor CB1, because a CB1 receptor antagonist (AM281) blocked the inhibitory effect of VU0360172 on synaptic inhibition. VU0360172 also increased and prolonged CB1-mediated depolarization-induced suppression of synaptic inhibition (DSI). Activation of CB1 with ACEA decreased inhibitory transmission through a presynaptic mechanism. The results show that increasing mGluR5 function enhances mPFC output. This effect can be accomplished by increasing excitability with an orthosteric agonist (CHPG) or by increasing excitatory synaptic drive and CB1-mediated presynaptic suppression of synaptic inhibition ("dis-inhibition") with a PAM (VU0360172). Therefore, mGluR5 may be a useful target in conditions of impaired mPFC output. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.

Indexed as

AnimalsArachidonic AcidsCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsExcitatory Amino Acid AgonistsExcitatory Amino Acid AntagonistsExcitatory Postsynaptic PotentialsGlycineInhibitory Postsynaptic PotentialsMaleMorpholinesNeural InhibitionNiacinamidePhenylacetatesPrefrontal CortexPyramidal Cells2-chloro-5-hydroxyphenylglycine3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridineAM 281Arachidonic Acidsarachidonyl-2-chloroethylamideCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsExcitatory Amino Acid AgonistsExcitatory Amino Acid AntagonistsGlycineGrm5 protein, ratMorpholinesN-cyclobutyl-6-((3-fluorophenyl)ethynyl)nicotinamideNiacinamidePhenylacetatesPyrazolesPyridinesReceptor, Cannabinoid, CB1Receptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateThiazoles

Identifiers

PMID22521499
PMCPMC3568505
OpenAlexW2014359029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.